AstraZeneca PLC $AZN Shares Acquired by Cibc World Market Inc.

Cibc World Market Inc. lifted its stake in shares of AstraZeneca PLC (NASDAQ:AZN) by 21.5% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 64,421 shares of the company’s stock after purchasing an additional 11,398 shares during the quarter. Cibc World Market Inc.’s holdings in AstraZeneca were worth $4,942,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in AZN. Chapin Davis Inc. grew its position in AstraZeneca by 3.3% during the third quarter. Chapin Davis Inc. now owns 3,795 shares of the company’s stock worth $291,000 after buying an additional 120 shares during the period. CoreCap Advisors LLC grew its holdings in shares of AstraZeneca by 30.6% in the 3rd quarter. CoreCap Advisors LLC now owns 534 shares of the company’s stock worth $41,000 after acquiring an additional 125 shares during the period. Highline Wealth Partners LLC increased its stake in AstraZeneca by 32.0% in the 3rd quarter. Highline Wealth Partners LLC now owns 532 shares of the company’s stock valued at $41,000 after purchasing an additional 129 shares in the last quarter. Traub Capital Management LLC increased its stake in AstraZeneca by 3.3% in the 3rd quarter. Traub Capital Management LLC now owns 4,115 shares of the company’s stock valued at $316,000 after purchasing an additional 130 shares in the last quarter. Finally, Aaron Wealth Advisors LLC raised its holdings in AstraZeneca by 0.6% during the third quarter. Aaron Wealth Advisors LLC now owns 21,215 shares of the company’s stock worth $1,628,000 after purchasing an additional 136 shares during the last quarter. Institutional investors and hedge funds own 20.35% of the company’s stock.

AstraZeneca Stock Performance

Shares of AZN opened at $205.47 on Friday. AstraZeneca PLC has a 1 year low of $122.48 and a 1 year high of $206.71. The company’s 50 day simple moving average is $112.72 and its 200 day simple moving average is $92.95. The company has a market capitalization of $318.66 billion, a price-to-earnings ratio of 68.26, a PEG ratio of 1.59 and a beta of 0.34. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.69 and a current ratio of 0.88.

AstraZeneca Announces Dividend

The business also recently disclosed a dividend, which will be paid on Monday, March 23rd. Stockholders of record on Friday, February 20th will be paid a dividend of $1.595 per share. The ex-dividend date of this dividend is Friday, February 20th. This represents a dividend yield of 165.0%. AstraZeneca’s dividend payout ratio is currently 74.83%.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on AZN shares. TD Cowen restated a “buy” rating on shares of AstraZeneca in a research report on Tuesday, December 9th. Deutsche Bank Aktiengesellschaft restated a “sell” rating on shares of AstraZeneca in a report on Friday, February 6th. Citigroup initiated coverage on shares of AstraZeneca in a report on Tuesday, January 27th. They issued a “buy” rating on the stock. Barclays reissued an “overweight” rating on shares of AstraZeneca in a research note on Tuesday, January 6th. Finally, Jefferies Financial Group initiated coverage on AstraZeneca in a research note on Monday, October 27th. They issued a “buy” rating on the stock. Nine investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $95.75.

AstraZeneca Company Profile

AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca’s operations span research and development, large-scale manufacturing, and commercial distribution, with a presence in developed and emerging markets worldwide.

The company focuses on several core therapy areas including oncology, cardiovascular, renal and metabolism (CVRM), respiratory and immunology, and rare diseases.